Candesartan cilexetil, hydrochlorothiazide (Atacand Plus)
Candesartan cilexetil, hydrochlorothiazide
Equity Pharmaceutical (Pty) Ltd
Registration
- Applicant
- Equity Pharmaceutical (Pty) Ltd
- Registrations
- 3
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Atacand plus 16/12,5 MG EACH TABLET CONTAINS CANDESARTAN CILEXETIL 16,0 mg HYDROCHLOROTHIAZIDE 12,5 mg | 16/12,5 mg | 35009835/7.1.3/0098 | Registered | Not determined | None |
| Atacand plus 32/12,5 MG EACH TABLET CONTAINS CANDESARTAN CILEXETIL 32,0 mg HYDROCHLOROTHIAZIDE 12,5 mg | 32/12,5 mg | 43092243/7.1.3/0922 | Registered | Not determined | None |
| Atacand plus 32/25 MG EACH TABLET CONTAINS CANDESARTAN CILEXETIL 32,0 mg HYDROCHLOROTHIAZIDE 25,0 mg | 32/25 mg | 43092343/7.1.3/0923 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Combination product
This product contains more than one active ingredient, so it has no single molecular structure.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.